Celltrion, founded in 2002 and headquartered in Incheon, South Korea, is a global biopharmaceutical company specialising in the development, manufacturing, and distribution of biosimilars. The company provides end-to-end solutions across the biopharmaceutical production chain, from research and development through regulatory approval to commercial distribution.
The firm is known for developing the world's first monoclonal antibody biosimilar, a product now approved in approximately 100 countries. Celltrion operates manufacturing facilities with an annual production capacity of 250,000 litres and maintains a production success rate exceeding 99%. The company serves multiple therapeutic areas, including immunology, oncology, haematology, ophthalmology, and endocrinology.
Celltrion invests approximately 20% of its revenue in research and development each year, with technical expertise spanning biosimilar development, biologics manufacturing, monoclonal antibody production, and regulatory affairs. It is Korea's largest manufacturer and exporter of biosimilars, with its products available in roughly 100 markets worldwide.
